Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accesswire.com/724555/Allysta-Pharmaceuticals-Inc-Announces-Completion-of-Enrollment-in-Phase-2b3-Clinical-Trial-OASIS-1-Evaluating-the-Efficacy-and-Safety-of-ALY688-Ophthalmic-Solution-in-Dry-Eye-Disease
https://www.accesswire.com/652578/Allysta-Pharmaceuticals-Inc-Announces-Initiation-of-Dosing-in-OASIS-1-Phase-2b3-Clinical-Trial-ALY688-301-Study-Evaluating-the-Efficacy-and-Safety-of-ALY688-Ophthalmic-Solution-in-Dry-Eye
https://www.accesswire.com/651136/Allysta-Pharmaceuticals-Inc-Announces-Start-of-Phase-1-Clinical-Trial-of-ALY688-SR-a-Novel-First-in-Class-Peptide-that-Targets-Adiponectin-Signaling
https://www.accesswire.com/620848/Allysta-Pharmaceuticals-Inc-Announces-Positive-Preclinical-Data-in-a-NASH-Model-Demonstrating-its-Adiponectin-Analogue-ALY688-Reduces-Liver-Fat-Inflammation-and-Fibrosis
https://www.accesswire.com/618835/Allysta-Pharmaceuticals-Inc-Announces-Positive-Results-from-its-Phase-12a-Clinical-Trial-of-ALY688-Ophthalmic-Solution-in-Dry-Eye-Disease